


Iovance IP Leadership Within T-cell Based Immunotherapy

Iovance IP Portfolio Summary:

- ✓ >25 granted or allowed US and international patents
- ✓ Compositions of matter for TIL products
- ✓ Methods of treatment in a broad range of cancers
- ✓ Manufacturing processes
- ✓ >700 patents and applications worldwide, including major pharmaceutical markets

We established our leadership within T cell-based immunotherapy by building and augmenting the patent rights for our proprietary tumor infiltrating lymphocyte (TIL) technology platform—developed internally and licensed from third parties.



Abbreviations: ICI, immune checkpoint inhibitors; IL-2, interleukin 2; IP, intellectual property; NMA-LD, non-myeloablative lymphoid depletion; TIL, tumor infiltrating lymphocytes

Broad, Iovance-Owned IP Around TIL Therapy

Iovance owns more than 25 U.S. patents related to TIL therapy, including patents directed to compositions and methods of treatment in a broad range of cancers, such as U.S. Patent Nos. 10,894,063; 10,517,894; 10,166,257; 10,130,659; 10,272,113; 10,420,799; 10,398,734; 10,537,595; 10,639,330; 10,463,697; 10,363,273; 10,695,372; 10,646,517; 10,653,723; 10,905,718; 10,953,046; 10,946,044; 10,953,047; 10,933,094; 10,946,045; 10,925,900; 10,918,666; 11,007,225; 11,007,226; 11,013,770; 11,026,974; 11,040,070; 11,052,115; 11,052,116; and 11,058,728.

Iovance also owns U.S. patents covering TIL manufactured from a tumor digest and the use thereof, such as U.S. Patent Nos. 11,007,225; 11,007,226; 11,052,115; 11,052,116; and 11,058,728; and others.

U.S. Pat. No. 11,058,728 specifically covers a method of treatment using expanded TILs manufactured from a tumor digest where the steps of expansion to cryopreservation of the infusion bag having a harvested TIL population include two expansion steps in which the second expansion step is performed within about 14 days.

Furthermore, Iovance owns U.S. patents covering the use of the combination of TIL and an anti-PD-1 antibody, such as U.S. Patent No. 10,272,113, or an anti-PD-L1 antibody, such as U.S. Patent No. 11,013,770.

Iovance's patent portfolio also includes patent applications relating to:

- ✓ Frozen tumor-based TIL technologies;
- ✓ Remnant TIL and digest TIL compositions;
- ✓ Use of co-stimulatory molecules in TIL therapy and manufacturing;
- ✓ Stable and transient genetically-modified TIL therapies;
- ✓ Methods of using immune checkpoint inhibitors in combination with TIL therapies;
- ✓ TIL selection technologies;
- ✓ Methods of treating patient subpopulations.

U.S. Patent/Application Information for Iovance Clinical Products

Product	Pursued Indication*	Composition of Matter	Method of Use	Method of Manufacturing	
Lifileucel (TIL)	Patients with metastatic melanoma or cervical cancer	US 10,894,063; US 10,398,734; US 10,537,595; US 10,695,372; US 10,653,723	US 10,166,257; US 10,130,659; US 10,272,113; US 10,463,697; US 10,363,273; US 10,646,517; US 10,905,718;	US 10,953,046; US 10,946,044; US 10,953,047; US 10,933,094; US 10,946,045; US 10,925,900; US 11,013,770	US 10,420,799; US 10,639,330; US 10,918,666
LN-145 (TIL)	Patients with metastatic melanoma, HNSCC, or NSCLC	US 10,894,063; US 10,398,734; US 10,537,595; US 10,695,372; US 10,653,723	US 10,166,257; US 10,130,659; US 10,272,113; US 10,463,697; US 10,363,273; US 10,646,517; US 10,905,718;	US 10,953,046; US 10,946,044; US 10,953,047; US 10,933,094; US 10,946,045; US 10,925,900; US 11,013,770	US 10,420,799; US 10,639,330; US 10,918,666
IOV-2001 (PBL)	Patients with CLL or SLL	WO 2020/180733 A1; US 2020/0224161 A1; US 2020/0347350 A1	WO 2020/180733 A1; US 2020/0224161 A1; US 2020/0347350 A1	WO 2020/180733 A1; US 2020/0224161 A1; US 2020/0347350 A1	

*Subject to FDA approval.

Abbreviations: CLL, chronic lymphocytic leukemia; HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small-cell lung cancer; SLL, small lymphocytic leukemia; TIL, tumor infiltrating lymphocytes.